Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

INTRODUCTION: In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: A ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Raymond, Fishman, Jesse, Wilson, Koo, Yeh, Michael, Al-Adhami, Mohammed, Zion, Abigail, Yee, Christopher W., Huynh, Lynn, Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070304/
https://www.ncbi.nlm.nih.gov/pubmed/36750531
http://dx.doi.org/10.1007/s12325-023-02438-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070304/
https://www.ncbi.nlm.nih.gov/pubmed/36750531
http://dx.doi.org/10.1007/s12325-023-02438-9

Ejemplares similares